With windfall sales driven by Covid testing behind, India's diagnostic players face a return to reality.Companies offering pathology and radiology services recorded a dip in revenues and margins in the first half of the fiscal as demand normalises on a high Covid base. And there are concerns that low entry barriers and competitive pricing with new players will further erode investor confidence.Still, Sriraam Rathi, India analyst-phar...